文献速递MDS 与骨髓增殖性肿瘤白血病

JAK2抑制剂治疗骨髓增殖性肿瘤:下一步是什么?

JAK2 inhibitors for myeloproliferative neoplasms: what is next?
PubMed 文献 · Blood · 2017-05-12

该综述回顾了JAK2抑制剂在骨髓增殖性肿瘤中的应用现状与未来方向。鲁索替尼自2011年获批后成为骨髓纤维化治疗的核心药物,在羟基脲耐药或不耐受的真性红细胞增多症中使用也稳步增加。JAK2抑制剂临床获益显著但疾病修饰作用有限,鲁索替尼为基础的联合方案可能是骨髓纤维化药物开发的主要方向。

要点

  • 鲁索替尼是骨髓纤维化治疗的核心药物,在羟基脲耐药或不耐受的真性红细胞增多症中使用稳步增加。
  • JAK2抑制剂的活性不限于JAK2 V617F或外显子12突变患者,但疾病修饰作用有限。
  • 鲁索替尼为基础的联合方案可能是骨髓纤维化药物开发的主要方向。

核心结论

  • 鉴于鲁索替尼已证实的疗效与安全性,鲁索替尼为基础的联合方案很可能是骨髓纤维化药物开发的主要方向。
  • 若获批,帕克替尼(pacritinib)或NS-018等骨髓抑制较少的JAK2抑制剂可能成为骨髓纤维化治疗武器库中非常有用的补充。
  • 在真性红细胞增多症中,组蛋白去乙酰化酶抑制剂和人双微体2抑制剂具有活性,但鉴于鲁索替尼的可及性及对干扰素的重新关注,其在未来治疗流程中的作用(如有)尚不确定。
  • 鲁索替尼正在原发性血小板增多症中开展后期临床试验,可能填补有困扰症状患者的重要空白。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 鲁索替尼自2011年获批以来已成为骨髓纤维化治疗的核心,在羟基脲耐药或不耐受的真性红细胞增多症患者中使用稳步增加。
  • 其他多种JAK2抑制剂已进入临床测试,但均未获批,许多已停止开发。
  • JAK2抑制剂的活性不限于JAK2 V617F或外显子12突变患者。
  • JAK2抑制剂提供显著临床获益,但疾病修饰活性有限,尤其在高死亡风险的骨髓纤维化中需要与其他靶向药物进行合理联合。
  • 多种此类联合方案正在探索中,其他新型药物也在研究中,其中一些未来可能成功与JAK2抑制剂联合。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing. Several other JAK2 inhibitors have entered clinical testing, but none have been approved and many have been discontinued. Importantly, the activity of these agents is not restricted to patients with JAK2 V617F or exon 12 mutations. Although JAK2 inhibitors provide substantial clinical benefit, their disease-modifying activity is limited, and rational combinations with other targeted agents are needed, particularly in MF, in which survival is short. Many such combinations are being explored, as are other novel agents, some of which could successfully be combined with JAK2 inhibitors in the future. In addition, new JAK2 inhibitors with the potential for less myelosuppression continue to be investigated. Given the proven safety and efficacy of ruxolitinib, it is likely that ruxolitinib-based combinations will be a major way forward in drug development for MF. If approved, less myelosuppressive JAK2 inhibitors such as pacritinib or NS-018 could prove to be very useful additions to the therapeutic armamentarium in MF. In PV, inhibitors of histone deacetylases and human double minute 2 have activity, but their role, if any, in the future treatment algorithm is uncertain, given the availability of ruxolitinib and renewed interest in interferons. Ruxolitinib is in late-phase clinical trials in essential thrombocythemia, in which it could fill an important void for patients with troublesome symptoms.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017. PMID: 28500170. doi:10.1182/blood-2017-04-742288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。